Biological E completes phase-2 covid vaccine trial, gets SEC nod for phase-3
- In the first and second phase of the trial, the Hyderabad-based vaccine maker studied the safety and immunogenicity of the vaccine candidate in about 360 participants in the age group of 18 to 65 years